Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Huntington's Disease

Inherited progressive neurodegenerative disorder causing movement, cognitive, and psychiatric symptoms. Cannabis has limited evidence for managing chorea, sleep, and pain in Huntington's patients; no disease-modifying effect.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: G10

What is Huntington's Disease?

Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene. Symptoms typically appear between ages 30 and 50 and include involuntary movements (chorea), cognitive decline, psychiatric symptoms (depression, irritability, psychosis), and progressive disability over 10–20 years. Inheritance is autosomal dominant; offspring of an affected parent have a 50% risk.

There is no cure. Tetrabenazine and deutetrabenazine are FDA-approved for chorea; antidepressants and antipsychotics manage psychiatric symptoms.

Does cannabis help Huntington's Disease?

Evidence for cannabis in Huntington's disease is limited. Small clinical studies of nabilone and CBD-THC formulations have reported modest improvements in chorea and behavioral symptoms in individual patients, but trials have not consistently demonstrated benefit on validated motor or functional rating scales.

Huntington's is a qualifying condition under several state medical cannabis programs, often under broader categories such as "incurable neurodegenerative disease" or "Huntington's disease" specifically. Use should be coordinated with the patient's neurologist and HD care team.

Eligibility

State eligibility for Huntington's Disease

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Huntington's Disease: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Not listed	Florida OMMU
Georgia	Not listed	Georgia DPH Low-THC Registry
Texas	Yes	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

Does cannabis slow Huntington's disease progression?

No. There is no clinical evidence that cannabis or cannabinoids slow or modify the underlying neurodegenerative process in Huntington's disease. Cannabis use in HD is symptomatic (addressing chorea, sleep disturbance, pain, and appetite) not disease-modifying.

Is any cannabis-derived product FDA-approved for Huntington's disease?

No. No cannabis or cannabinoid medication is FDA-approved for Huntington's disease. FDA-approved chorea treatments are tetrabenazine and deutetrabenazine, which target vesicular monoamine transporter 2 (VMAT2). Unrelated to the cannabinoid system.

Which HD symptoms have the most cannabis-related evidence?

Available studies (most small and observational) describe cannabis use for chorea, sleep disturbance, pain, anxiety, and appetite stimulation. Evidence quality is limited across all symptom domains; randomized controlled trials in HD are scarce. Patients commonly combine cannabis with standard HD pharmacotherapy rather than replacing it.

What practical considerations apply when HD patients use cannabis?

HD patients often take antipsychotics, antidepressants, and chorea-control medications. All of which can interact with cannabis through cytochrome P450 metabolism and additive CNS effects. Sedation, cognitive effects, and orthostatic hypotension are heightened concerns. Caregivers should coordinate cannabis use with the neurology team, particularly during dose changes.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.